Keyuan Pharmaceutical's wholly-owned subsidiary, Linuo Pharmaceutical, recently received drug registration certificates and supplementary application approval notices from the National Medical Products Administration, covering three products: isosorbide dinitrate injection, esmolol hydrochloride injection, and betahistine hydrochloride tablets. Isosorbide dinitrate injection is indicated for unstable angina, vasospastic angina, acute myocardial infarction, and acute left ventricular failure. Esmolol hydrochloride injection is used for supraventricular tachycardia and tachycardia and hypertension during and after surgery. Betahistine hydrochloride tablets treat vertigo, tinnitus, and hearing loss associated with Ménière's disease. As of now, 19 companies have passed or are deemed to have passed the consistency evaluation for isosorbide dinitrate injection, 29 for esmolol hydrochloride injection, and 6 for betahistine hydrochloride tablets. In the first quarter of 2026, Keyuan Pharmaceutical achieved revenue of 161 million yuan and a net profit attributable to the parent company of 30.07 million yuan.
Shandong Keyuan Pharmaceutical Co. Ltd. ASubsidiary obtained drug registration certificates and supplementary approvals for three products from NMPA, enabling commercialization.